https://www.selleckchem.com/products/BIBR1532.html
Immune checkpoint inhibitors that block programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have improved outcomes for many cancer subtypes but do exhibit toxicity, in the form of immune-related adverse events. The aim of this study was to investigate the emerging toxicities of PD-1 and PD-L1 inhibitors including acute or reactivation of tuberculosis (T and atypical mycobacterial infection (AMI). This study was completed as a retrospective review using the US Food and Drug Administration Adverse Events Reporting
Like
Comment
Share
